Agios Pharmaceuticals Liabilities 2024

Agios Pharmaceuticals Aktienanalyse

What does Agios Pharmaceuticals do?

Agios Pharmaceuticals Inc. is a US biopharmaceutical company specializing in the development of treatment options for rare genetic disorders and cancer. The company was founded in 2008 by David Schenkein, Lewis Cantley, and Tak Mak and is headquartered in Cambridge, Massachusetts. The history of Agios Pharmaceuticals Inc. began with the discovery of IDH1 mutations, which are frequently found in many types of cancer. The founders of Agios recognized the significance of this discovery and laid the foundation for the development of drugs targeting this mutation. Agios' business model is to develop innovative therapeutics for diseases that are often neglected by other companies. The company focuses on researching enzymes that play important roles in genetic disorders and cancer processes. Agios collaborates closely with other companies and research institutions to quickly translate its research findings into clinical research and subsequent patient treatment. Additionally, the company has established itself as a pioneer in the application of artificial intelligence in drug development in recent years. Agios divides its portfolio into two main areas: oncology and rare genetic disorders. In oncology, the company utilizes targeted therapies based on a deep understanding of the underlying cancer biology. Therapeutic approaches include enzyme inhibitors, immunotherapies, and cell therapies. Agios has several promising candidates in clinical development in this area, including Idhifa for the treatment of acute myeloid leukemia, as well as Ivosidenib and Ag-120, both used to treat brain tumors. In the field of rare genetic disorders, Agios specializes in a group of enzyme defects known as citric acid cycle disorders. Agios is the only provider of drugs targeting these enzymes. The company recently received approval for Tibsovo for the treatment of acute myeloid leukemia in the United States. Agios aims to continuously expand its pipeline of therapeutics to meet the unmet need for treatments for rare diseases and cancer. The company has an extensive research pipeline, with several drugs in preclinical and clinical development. Agios works closely with other companies and research institutions to quickly translate its research findings into clinical development and subsequent patient treatment. Overall, Agios Pharmaceuticals has made impressive strides in recent years and has established itself as a key player in the biopharmaceutical industry. The company specializes in developing innovative therapies for rare genetic disorders and cancer and collaborates closely with other companies and research institutions. With its extensive research pipeline and the application of artificial intelligence, Agios is well-positioned to contribute to the development of new therapeutic options in the future. Agios Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Agios Pharmaceuticals's Liabilities

Agios Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Agios Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Agios Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Agios Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Agios Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Agios Pharmaceuticals Stock

What is the level of liabilities of Agios Pharmaceuticals this year?

Agios Pharmaceuticals has a debt balance of 126.1 M USD this year.

What were the liabilities of Agios Pharmaceuticals compared to the previous year?

The liabilities of Agios Pharmaceuticals have increased by -8.56% dropped compared to the previous year.

What are the consequences of high debt for investors of Agios Pharmaceuticals?

High liabilities can pose a risk for investors of Agios Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Agios Pharmaceuticals?

Low liabilities mean that Agios Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Agios Pharmaceuticals affect the company?

An increase in liabilities of Agios Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Agios Pharmaceuticals affect the company?

A decrease in the liabilities of Agios Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Agios Pharmaceuticals?

Some factors that can influence the liabilities of Agios Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Agios Pharmaceuticals so important for investors?

The liabilities of Agios Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Agios Pharmaceuticals take to modify the liabilities?

To change its liabilities, Agios Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Agios Pharmaceuticals pay?

Over the past 12 months, Agios Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Agios Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Agios Pharmaceuticals?

The current dividend yield of Agios Pharmaceuticals is .

When does Agios Pharmaceuticals pay dividends?

Agios Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Agios Pharmaceuticals?

Agios Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Agios Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Agios Pharmaceuticals located?

Agios Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Agios Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Agios Pharmaceuticals from 6/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/19/2024.

When did Agios Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/19/2024.

What was the dividend of Agios Pharmaceuticals in the year 2023?

In the year 2023, Agios Pharmaceuticals distributed 0 USD as dividends.

In which currency does Agios Pharmaceuticals pay out the dividend?

The dividends of Agios Pharmaceuticals are distributed in USD.